Facebook Linkedin Mail Twitter Youtube
Facebook Linkedin Mail Twitter Youtube

Tag: TGD001

TargED doses first participant in Phase 1 clinical trial of “groundbreaking”...

TargED Biopharmaceuticals has today announced that it has commenced clinical development with the dosing of the first participant with TGD001—a “groundbreaking” thrombolytic designed to...
NeuroNews

Write to us
Editor: Jamie Bell [email protected]
Advertising: Abbie Richardson [email protected]


United Kingdom:

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: [email protected]

United States:

BIBA Medical, North America
155 North Wacker Drive, Suite 4250, Chicago, IL 60606
TEL: +1 949 723 9309
Email: [email protected]

Terms and Conditions | Privacy Policy

Facebook Linkedin Mail Twitter Youtube